STOCK TITAN
  1. Home
  2. News
  3. SPRC

SciSparc Ltd. Ordinary Shares - SPRC STOCK NEWS

Welcome to our dedicated page for SciSparc Ltd. Ordinary Shares news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on SciSparc Ltd. Ordinary Shares stock.

SciSparc Ltd. (Nasdaq: SPRC) is a specialty clinical-stage pharmaceutical company dedicated to developing innovative therapies for disorders of the central nervous system. With a strong focus on cannabinoid pharmaceuticals, the company is engaged in pioneering drug development programs targeting conditions like Tourette Syndrome, Alzheimer's disease, pain, Autism Spectrum Disorder (ASD), and status epilepticus using both THC and non-psychoactive CBD.

The company's robust pipeline includes SCI-110 for treating Tourette Syndrome and Alzheimer's agitation, SCI-160 for pain management, and SCI-210 for ASD and status epilepticus. Recently, SciSparc enrolled the first patient in its clinical trial for SCI-210, aimed at treating children with ASD.

In addition to drug development, SciSparc owns a subsidiary focused on online sales of hemp-based wellness products, including gummies, oils, capsules, and creams.

SciSparc's commitment to scientific excellence is highlighted by its collaborations and partnerships. For example, its venture with MitoCareX Bio leverages advanced computational platforms for cancer drug discovery, targeting mitochondrial SLC25 proteins.

The company is also actively expanding its intellectual property portfolio, with recent patents granted in the U.S., Canada, and Europe. These patents cover innovative compositions that enhance the therapeutic effects of cannabinoids while reducing side effects, thereby boosting its competitive edge globally.

Latest News:

  • March 8, 2024: First patient enrolled in ASD clinical trial for SCI-210.
  • March 12, 2024: MitoCareX Bio screens millions of small molecules for potential anti-cancer treatments.
  • March 14, 2024: First patient dosed in SCI-210 ASD trial.
  • March 18, 2024: Granted Canadian patent for cannabinoid and n-acylethanolamine compositions.
  • March 27, 2024: Clearmind partnership leads to multiple new patent applications.
  • May 31, 2024: European Patent Office grants patent for antimicrobial compositions.
News

SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering

Rhea-AI Summary
SciSparc Ltd. (SPRC) Announces Pricing of $1.3M Public Offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-62.83%
Tags
offering
-
News

SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million

Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) plans to offer its securities in a public offering to raise funds for working capital. The offering is subject to market conditions and the size and terms are uncertain. Aegis Capital Corp. will have the option to purchase additional shares. Interested parties should read the prospectus for more information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-62.83%
Tags
offering
-
News

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

Rhea-AI Summary
SciSparc Ltd. (Nasdaq: SPRC) and Clearmind Medicine Inc. (Nasdaq: CMND) filed a U.S. patent application for using the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia, including in Tourette Syndrome and Parkinson's disease. This collaboration aims to develop novel therapies for movement disorders, emphasizing SciSparc's commitment to pioneering innovative treatments for conditions with unmet need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
none
News

SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder

Rhea-AI Summary
SciSparc Ltd. has received approval from the Israeli Medical Cannabis Agency to conduct a clinical trial for SCI-210 in children with autism spectrum disorder. The company aims to sell SCI-210 first in Israel and then globally. The trial will compare SCI-210 to CBD monotherapy and evaluate safety, tolerability, and efficacy. The trial design includes 60 children and has three primary efficacy endpoints. ASD is a condition that affects social interaction and communication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
clinical trial
-
News

SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.95%
Tags
clinical trial
-
News

SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News

SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
none
-
News

SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
News

SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial

Rhea-AI Summary
SciSparc announces positive topline results from Phase IIa trial of SCI-110 for Alzheimer's disease and agitation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.94%
Tags
clinical trial
News

SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
management

FAQ

What is the current stock price of SciSparc Ltd. Ordinary Shares (SPRC)?

The current stock price of SciSparc Ltd. Ordinary Shares (SPRC) is $0.246 as of November 7, 2024.

What is the market cap of SciSparc Ltd. Ordinary Shares (SPRC)?

The market cap of SciSparc Ltd. Ordinary Shares (SPRC) is approximately 2.6M.

What does SciSparc Ltd. do?

SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for central nervous system disorders.

What are SciSparc's main drug development programs?

SciSparc's main programs include SCI-110 for Tourette Syndrome and Alzheimer's agitation, SCI-160 for pain, and SCI-210 for ASD and status epilepticus.

What recent achievements has SciSparc announced?

Recent achievements include enrolling the first patient in the SCI-210 ASD trial, obtaining a Canadian patent, and expanding partnerships with MitoCareX Bio and Clearmind.

What products does SciSparc offer online?

SciSparc's subsidiary sells hemp-based products like gummies, oils, capsules, and creams on Amazon Marketplace.

Where is SciSparc Ltd. based?

SciSparc Ltd. is based in Tel Aviv, Israel.

Is SciSparc involved in cancer research?

Yes, through its venture MitoCareX Bio, SciSparc is involved in cancer drug discovery targeting mitochondrial SLC25 proteins.

What patents has SciSparc recently secured?

SciSparc has recently secured patents in the U.S., Canada, and Europe for cannabinoid compositions and antimicrobial methods.

Who leads SciSparc Ltd.?

SciSparc Ltd. is led by a team of experienced senior executives and scientists.

What is SCI-210?

SCI-210 is a proprietary treatment combining cannabidiol (CBD) and CannAmide™ for Autism Spectrum Disorder and status epilepticus.

What is the significance of SciSparc's new patents?

The new patents strengthen SciSparc's intellectual property portfolio and enhance its position in the global pharmaceutical market.

Stock SPRC logo
SciSparc Ltd. Ordinary Shares

Nasdaq:SPRC

SPRC Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

SPRC Stock Data

2.57M
2.70M
0%
1.33%
3.51%
Biotechnology
Healthcare
Link
United States of America
Tel Aviv